2022 World Conference on Lung Cancer (ePosters)-EP08.01-059. Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer

EP08.01-059. Safety, Tolerability and Clinical Activity of Selinexor in Combination with Pembrolizumab in Metastatic Non-small Cell Lung Cancer

Back to course

Pdf Summary

A combination of Selinexor and Pembrolizumab has shown promising results in patients with metastatic Non-Small Cell Lung Cancer (mNSCLC), even in those previously treated with anti-PD-(L)1 therapy. The study aimed to determine the safety and efficacy of this combination therapy. The analysis included 17 patients, most of whom (88%) had received more than two prior lines of systemic therapy and 59% had previously been exposed to anti-PD-1/PD-L1 therapy. The median age of the patients was 67.5 years, with the majority having adenocarcinoma (82%). <br /><br />The results showed that 10 patients experienced grade 3 or higher treatment-related adverse events. However, responses to the treatment were observed in patients regardless of their previous exposure to anti-PD-1/PD-L1 therapy. The median overall survival was 11.4 months and the median progression-free survival was 3.0 months. The disease control rate was 47%. Overall, the safety and tolerability of the combination therapy were consistent with prior safety data for both drugs, with no overlapping toxicities observed.<br /><br />This study provides preliminary evidence of the potential of combining Selinexor and Pembrolizumab in the treatment of mNSCLC. The results suggest that this combination could be a promising strategy to overcome resistance to anti-PD-(L)1 therapy. Further detailed safety and clinical data will be presented in the final analysis.

Asset Subtitle

Mehmet Altan

Meta Tag

Speaker Mehmet Altan

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Selinexor

Pembrolizumab

metastatic Non-Small Cell Lung Cancer

mNSCLC

anti-PD-(L)1 therapy

combination therapy

safety and efficacy

treatment-related adverse events

overall survival

progression-free survival